Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 14/20 | 0.57 |
| ▸ | CTSK | P43235 | 13/20 | 0.57 |
| ▸ | CTSS | P25774 | 12/20 | 0.57 |
| ▸ | CTSB | P07858 | 10/20 | 0.57 |
| ▸ | GRN | P28799 | 1/20 | 0.46 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.46 |
| ▸ | ACE | P12821 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2130836 | 0.89 | CTSL (0.56) | CTSLCTSKCTSSCTSBGRN | |
| SCHEMBL2130840 | 0.89 | CTSL (0.56) | CTSLCTSKCTSSCTSBGRN | |
| SCHEMBL2131045 | 0.87 | CTSL (0.61) | CTSLCTSKCTSSCTSBGRN | |
| SCHEMBL4419936 | 0.87 | CTSL (0.61) | CTSLCTSKCTSSCTSBGRN | |
| SCHEMBL1169217 | 0.84 | CTSL (0.72) | CTSLCTSKCTSSCTSBGRN | |
| SCHEMBL4085485 | 0.84 | CTSL (0.72) | CTSLCTSKCTSSCTSBGRN | |
| SCHEMBL4085479 | 0.84 | CTSL (0.72) | CTSLCTSKCTSSCTSBGRN | |
| SCHEMBL1169219 | 0.84 | CTSL (0.72) | CTSLCTSKCTSSCTSBGRN | |
| SCHEMBL4786346 | 0.84 | CTSL (0.72) | CTSLCTSKCTSSCTSBGRN | |
| SCHEMBL2156284 | 0.81 | CTSL (0.60) | CTSLCTSKCTSSCTSBGRN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120101053-A1 | CATHEPSIN CYSTEINE PROTEASE INHIBITORS FOR THE TREATMENT OF VARIOUS DISEASES | MERCK CANADA INC. (CA) | 2012-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120101053-A1 | CATHEPSIN CYSTEINE PROTEASE INHIBITORS FOR THE TREATMENT OF VARIOUS DISEASES | CTSL, CTSS, CTSZ | CTSL 1/4885CTSK 14/4885CTSS 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.